This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Today's Health Winners and Losers

Shares of Nanogen (NGEN) were among the best-performing health-related stocks Wednesday, climbing 20% after the company's congestive heart failure test received Food and Drug Administration approval.

The company's StatusFirst plasma test is its first product to receive FDA marketing approval. "This is the first 510(k) clearance earned by Nanogen and is a significant milestone," the company said. "The StatusFirst CHF 510(k) plasma clearance will permit us to begin the commercial launch of our CHF test." The product was brought to market through a collaboration of Nanogen and Princeton BioMeditech. Shares were trading up 54 cents to $3.24.

Shares of LanVision Systems (LANV), which does business as Streamline Health, rose 3% after the company reported a big jump in fourth-quarter earnings. The company, which provides software used by medical professionals, earned $2.7 million, or 29 cents a share, on revenue of $6.2 million. A single analyst polled by Thomson First Call expected a profit of 11 cents a share on revenue of $6.2 million. During the year-earlier quarter, the company earned $1.6 million, or 17 cents a share, on revenue of $5 million.

For all of fiscal 2005, the company's earnings rose to $2.6 million, or 27 cents a share, from $558,000, or 6 cents a share, a year earlier. Revenue grew to $16.1 million from $12.8 million. Shares were up 23 cents to $7.90.

Despite announcing a licensing agreement that could potentially be worth up to $525 million, Idenix Pharmaceuticals (IDIX) slid 4% Wednesday. Novartis (NVS), which owns about 56% of Idenix, exercised its option to license Idenix's valopicitabine compound, an oral antiviral that is in development as a hepatitis C treatment. "Our collaboration with Novartis contributes additional clinical, regulatory and marketing expertise to these efforts, as well as funding for this development program," Idenix said.

Under the agreement, Idenix is eligible to receive up to $70 million in license fees, including $25 million that is payable in connection with the option exercise. Additionally, Idenix could receive up to $455 million in milestone payments that are tied to regulatory filing and marketing approvals in the U.S., Europe and Japan. Shares of Idenix were down 55 cents to $13.54.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,472.23 +72.56 0.44%
S&P 500 1,911.97 +7.96 0.42%
NASDAQ 4,359.2290 +43.1550 1.00%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs